Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis
Top Cited Papers
Open Access
- 1 October 2006
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 63 (10) , 1383-1387
- https://doi.org/10.1001/archneur.63.10.1383
Abstract
Research from JAMA Neurology — Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple SclerosisKeywords
This publication has 26 references indexed in Scilit:
- Immune surveillance in multiple sclerosis patients treated with natalizumabAnnals of Neurology, 2006
- Natalizumab effects on immune cell responses in multiple sclerosisAnnals of Neurology, 2006
- Multiple Sclerosis — The Plaque and Its PathogenesisNew England Journal of Medicine, 2006
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with NatalizumabNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple SclerosisNew England Journal of Medicine, 2005
- A Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2003
- A safety and pharmacokinetic study of intravenous natalizumab in patients with MSNeurology, 1999
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983